Huahui Health

Huahui Health was founded in Beijing in 2015. Adhering to the principles of "innovation, pragmatism, cooperation, and win-win," the company is rooted in science and centers on patient needs, committing to the development of "first-in-class" or "best-in-class" novel drugs. Dr. Wenwei Li, the founder, and his team discovered the cellular receptor for hepatitis B and D viruses—the sodium taurocholate cotransporting polypeptide (NTCP). Based on this discovery, the company is developing new anti-hepatitis B drugs with novel targets and mechanisms to achieve functional cures for chronic hepatitis B. While focusing on major liver diseases such as hepatitis B, the company actively expands its R&D pipeline into areas like anti-COVID-19 and anti-cancer therapies. We are confident in discovering, developing, and commercializing innovative drugs with global intellectual property rights, growing into a biopharmaceutical company based in China with an international presence and future global influence and competitiveness, allowing innovative products from China to benefit patients worldwide.